473 related articles for article (PubMed ID: 24677326)
1. Enhanced immunoprotective effects by anti-IL-17 antibody translates to improved skeletal parameters under estrogen deficiency compared with anti-RANKL and anti-TNF-α antibodies.
Tyagi AM; Mansoori MN; Srivastava K; Khan MP; Kureel J; Dixit M; Shukla P; Trivedi R; Chattopadhyay N; Singh D
J Bone Miner Res; 2014 Sep; 29(9):1981-92. PubMed ID: 24677326
[TBL] [Abstract][Full Text] [Related]
2. Daidzein prevents the increase in CD4+CD28null T cells and B lymphopoesis in ovariectomized mice: a key mechanism for anti-osteoclastogenic effect.
Tyagi AM; Srivastava K; Sharan K; Yadav D; Maurya R; Singh D
PLoS One; 2011; 6(6):e21216. PubMed ID: 21731677
[TBL] [Abstract][Full Text] [Related]
3. Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency.
Kanematsu M; Sato T; Takai H; Watanabe K; Ikeda K; Yamada Y
J Bone Miner Res; 2000 Jul; 15(7):1321-9. PubMed ID: 10893680
[TBL] [Abstract][Full Text] [Related]
4. Methoxyisoflavones formononetin and isoformononetin inhibit the differentiation of Th17 cells and B-cell lymphopoesis to promote osteogenesis in estrogen-deficient bone loss conditions.
Mansoori MN; Tyagi AM; Shukla P; Srivastava K; Dev K; Chillara R; Maurya R; Singh D
Menopause; 2016 May; 23(5):565-76. PubMed ID: 27070807
[TBL] [Abstract][Full Text] [Related]
5. A monoclonal antibody ameliorates local inflammation and osteoporosis by targeting TNF-α and RANKL.
Qian H; Yuan H; Wang J; Du Y; Zhang X; Sun Y; Li Z; Zhao W
Int Immunopharmacol; 2014 Jun; 20(2):370-6. PubMed ID: 24726242
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of anti-IL-23 monotherapy versus combination therapy with anti-IL-17 in estrogen deficiency induced bone loss conditions.
Shukla P; Mansoori MN; Singh D
Bone; 2018 May; 110():84-95. PubMed ID: 29414600
[TBL] [Abstract][Full Text] [Related]
7. Engineering and characterization of a humanized antibody targeting TNF-α and RANKL.
Wang J; Du Y; Qian H; Yu H; Li S; Zhang X; Li Z; Yuan H; Zhao W
Biochem Biophys Res Commun; 2014 Jul; 450(1):717-22. PubMed ID: 24950406
[TBL] [Abstract][Full Text] [Related]
8. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
9. Receptor activator of nuclear factor-κB ligand is a novel inducer of myocardial inflammation.
Ock S; Ahn J; Lee SH; Park H; Son JW; Oh JG; Yang DK; Lee WS; Kim HS; Rho J; Oh GT; Abel ED; Park WJ; Min JK; Kim J
Cardiovasc Res; 2012 Apr; 94(1):105-14. PubMed ID: 22298642
[TBL] [Abstract][Full Text] [Related]
10. Estrogen regulation of immune cell bone interactions.
Weitzmann MN; Pacifici R
Ann N Y Acad Sci; 2006 Apr; 1068():256-74. PubMed ID: 16831927
[TBL] [Abstract][Full Text] [Related]
11. Bu‑Shen‑Ning‑Xin decoction suppresses osteoclastogenesis by modulating RANKL/OPG imbalance in the CD4+ T lymphocytes of ovariectomized mice.
Zhang JL; Qiu XM; Zhang N; Tang W; Gober HJ; Li DJ; Wang L
Int J Mol Med; 2018 Jul; 42(1):299-308. PubMed ID: 29717766
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis.
Wong PK; Quinn JM; Sims NA; van Nieuwenhuijze A; Campbell IK; Wicks IP
Arthritis Rheum; 2006 Jan; 54(1):158-68. PubMed ID: 16385511
[TBL] [Abstract][Full Text] [Related]
13. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
[TBL] [Abstract][Full Text] [Related]
14. IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-alpha antibody: a novel mechanism of osteoclastogenesis by IL-17.
Yago T; Nanke Y; Ichikawa N; Kobashigawa T; Mogi M; Kamatani N; Kotake S
J Cell Biochem; 2009 Nov; 108(4):947-55. PubMed ID: 19728295
[TBL] [Abstract][Full Text] [Related]
15. Adipose-Derived Mesenchymal Stem Cells Prevent Systemic Bone Loss in Collagen-Induced Arthritis.
Garimella MG; Kour S; Piprode V; Mittal M; Kumar A; Rani L; Pote ST; Mishra GC; Chattopadhyay N; Wani MR
J Immunol; 2015 Dec; 195(11):5136-48. PubMed ID: 26538398
[TBL] [Abstract][Full Text] [Related]
16. Liver-derived IGF-I is permissive for ovariectomy-induced trabecular bone loss.
Lindberg MK; Svensson J; Venken K; Chavoshi T; Andersson N; Movérare Skrtic S; Isaksson O; Vanderschueren D; Carlsten H; Ohlsson C
Bone; 2006 Jan; 38(1):85-92. PubMed ID: 16257281
[TBL] [Abstract][Full Text] [Related]
17. Bone and the Immune System.
Weitzmann MN
Toxicol Pathol; 2017 Oct; 45(7):911-924. PubMed ID: 29046115
[TBL] [Abstract][Full Text] [Related]
18. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion.
Lubberts E; Koenders MI; Oppers-Walgreen B; van den Bersselaar L; Coenen-de Roo CJ; Joosten LA; van den Berg WB
Arthritis Rheum; 2004 Feb; 50(2):650-9. PubMed ID: 14872510
[TBL] [Abstract][Full Text] [Related]
19. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.
Kon T; Cho TJ; Aizawa T; Yamazaki M; Nooh N; Graves D; Gerstenfeld LC; Einhorn TA
J Bone Miner Res; 2001 Jun; 16(6):1004-14. PubMed ID: 11393777
[TBL] [Abstract][Full Text] [Related]
20. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
